HbA1c Testing Market

Global HbA1c Testing Market Size (2024 to 2032)

In 2023, the global HbA1c testing market was valued at USD 1.8 billion and it is expected to reach USD 4.60 billion by 2032 from USD 2 billion in 2024, growing at a CAGR of 11 % during the forecast period.

HbA1c is a modified form of an oxygen-carrying pigment in red blood cells called hemoglobin. Most hemoglobin is in HbA form, but a small fraction transforms into HbA1 during their lifespans. In further findings, scientists discovered in the 1950s that HbA1 could further be separated into HbA1a, HbA1c, and HbA1c. Patients with diabetes have an alarmingly high level of HbA1c in their bodies as its formation occurs only during a process called glycosylation, which involves converting glucose into glycogen for storage purposes.

MARKET DRIVERS

The growing incidence of diabetes is one of the key factors propelling the HbA1c testing market.

The number of people affected by diabetes increases exponentially daily due to poor dietary choices, lack of physical activities, and high stress levels. As a result, physicians are increasingly prescribing HbA1c tests to their patients, which is expected to drive the market revenue for HbA1c Testing. Moreover, the emergence of point of care and other new devices to lower the cost of diabetes testing is further expected to aid the HbA1c Testing Market growth.

The growing aging population worldwide is fueling the growth rate of the global HbA1c testing market.

The senior population is increasing continually, leading to a rise in diabetic patients' accounts worldwide. Innovative testing procedures and handheld devices due to technological advancements are expected to provide lucrative opportunities for the HbA1c testing market stakeholders. The increased scope of medical tourism in developing countries is likely to boost the HbA1c testing market opportunities. Growing awareness among people to manage diabetes efficiently is expected to offer growth opportunities for the key players in the market.

Increasing demand for handheld analyzers and proliferated diagnostic laboratories in remote locations of countries like India and China are expected to provide lucrative growth opportunities for the HbA1c market during the forecast period. In addition, the rise in the affordability of testing devices in hospitals due to patient footfalls will likely provide more opportunities for the HbA1c testing market's growth during the forecast period. Prevalence for early disease diagnosis among people also lavishes the market's growth. 

MARKET RESTRAINTS

The devices used for testing are costly. The adoption of these technologies is minimal in developing countries, which is expected to limit the growth of the HbA1c testing market. Manufacturing costs of these devices are high resulting in limited production of HbA1c testing devices, posing a challenge to the key players in the HbA1c market. Another major challenge is inaccuracies in the testing due to discrepancies in interpretations expected to resist the market's growth during the forecast period. Stringent rules and regulations by the government may also negatively impact the HbA1c Testing Market's growth rate. 

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global HbA1c Testing Market Analysis By Technology

The affinity binding chromatography segment held the largest share in the HbA1c testing market in 2023, owing to the increasing investments and support. 

The Ion-Exchange HPCL segment is another lucrative segment in the global HbA1C market. Due to the various advantages over other technologies, Ion exchange is most widely used for HbA1c testing. The HPLC consumes less time, recognizes variants, and is utilized in Point-of-care settings.  

The Turbidimetric inhibition immunoassay is anticipated to grow healthy during the forecast period. The segment provides accurate results; it is cost-effective and quick swiftness. 

Global HbA1c Testing Market Analysis By Type

The benchtop devices segment had the largest share of the global market in 2023, and the lead of the segment is expected to continue throughout the forecast period due to its fast and accurate results.  

Global HbA1c Testing Market Analysis By End-User

The homecare segment is projected to account for most of the market share during the forecast period due to the rising popularity of home care services, a crucial factor governing this segment's growth. Furthermore, escalating preference for diabetic patients regarding self-monitoring HbA1clevels and the capability of the tests to provide quick outputs favors the segment to excel more.

REGIONAL ANALYSIS

As of 2023, North America accounted for the largest share of the HbA1c Testing market, followed by Europe and the Asia Pacific. However, the Asia Pacific is projected to register the highest growth rate in the coming years due to diabetes's growing cases of diabetes. Moreover, low healthcare costs are crucial in boosting medical tourism in the region, which will aid market growth.

KEY PLAYERS IN THE GLOBAL HBA1C TESTING MARKET

The promising companies leading the Global HbA1c Testing Market profiled in this report are Transasia Biomedicals Ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, and Trinity Biotech plc.

RECENT HAPPENINGS IN THE MARKET

• Bio-Rad Laboratories Inc. conducted a D-10 HbA1c program for identifying and diagnosing diabetic patients. The FDA approved this program in July 2017. With this approval, the adoption rate of D-10 HbA1c testing systems has been escalated due to their ability to diagnose diabetic patients.
• Seimens healthiness developed Atellica CH Enzymatic HbA1c Assay for monitoring and diagnosing diabetes. The FDA approved it, and the product was launched in May 2019. These instruments are implemented in laboratories to acquire higher efficiency and productivity by conducting tests on more significant volumes.

DETAILED SEGMENTATION OF THE GLOBAL HBA1C TESTING MARKET INCLUDED IN THIS REPORT

This research report on the global HbA1c testing market has been segmented and sub-segmented based on the technology, type, end-user, and region.

By Technology

• Ion-Exchange HPCL             
• Enzymatic Assay   
• Affinity Binding Chromatography  
• Turbidimetric Inhibition Immunoassay       
• Other       

By Type

• Hand-Held Devices               
• Bench Top Devices         

By End User

• Hospital    
• Home Care              
• Diagnostic laboratory          
• Research Institution            

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa